{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:08:08Z","timestamp":1790809688551,"version":"4.1.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bedaquiline has transformed the treatment of multidrug-resistant tuberculosis (MDR-TB). However, bedaquiline resistance now threatens these gains. Emerging surveillance data demonstrate both baseline and acquired resistance across high-burden settings, with bedaquiline-resistant disease associated with poor clinical outcomes, high mortality, and growing evidence of transmission. In this Perspective, we examine the converging factors driving this trend, including bedaquiline's unique pharmacokinetic properties and limitations of current drug-susceptibility testing (DST) approaches. We describe critical gaps in phenotypic and genotypic DST, including delayed detection, diagnostic gray zones, and heteroresistance, which undermine timely clinical decision-making. We highlight the need to evaluate bedaquiline-sparing regimens alongside strengthened resistance surveillance, development of composite DST standards, and adoption of rapid molecular tools such as targeted next-generation sequencing. We emphasize the importance of equitable access to effective companion drugs and robust, person-centered treatment support. Coordinated action across clinical, programmatic, and research domains is essential to preserve bedaquiline's efficacy and future TB treatments.<\/jats:p>","DOI":"10.1093\/cid\/ciag008","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:28:38Z","timestamp":1767702518000},"page":"e1326-e1332","source":"Crossref","is-referenced-by-count":2,"title":["We Are Underprepared for Bedaquiline Resistance: A Call for Clinical and Programmatic Readiness"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5116-9576","authenticated-orcid":false,"given":"Gail Brenda","family":"Cross","sequence":"first","affiliation":[{"name":"Tuberculosis Working Group, Burnet Institute , Victoria ,","place":["Australia"]},{"name":"Monash Infectious Diseases Service, Monash Health , Victoria ,","place":["Australia"]},{"name":"School of Clinical Sciences, Monash University , Victoria ,","place":["Australia"]},{"name":"The Kirby Institute, UNSW Sydney , New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8313-9822","authenticated-orcid":false,"given":"Harry N","family":"Walker","sequence":"additional","affiliation":[{"name":"Department of Medicine (Infectious Diseases), Central Queensland Hospital and Health Service , Queensland ,","place":["Australia"]},{"name":"Pathology Queensland, Rockhampton , Queensland ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6407-8155","authenticated-orcid":false,"given":"Tasnim","family":"Hasan","sequence":"additional","affiliation":[{"name":"Blacktown Hospital, Western Sydney Local Health District , Sydney, New South Wales ,","place":["Australia"]},{"name":"Sydney Infectious Disease Institute, Faculty of Healthy and Medicine, University of Sydney , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Berry","sequence":"additional","affiliation":[{"name":"Department of Medicine (Infectious Diseases), John Hunter Hospital, Hunter-New England Local Health District , Newcastle, New South Wales ,","place":["Australia"]},{"name":"School of Medicine and Public Health, University of Newcastle , Newcastle, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"2026070722330594000_ciag008-B1","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa2400327","article-title":"Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis","volume":"392","author":"Guglielmetti","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070722330594000_ciag008-B2","doi-asserted-by":"publisher","author":"Conradie","DOI":"10.1101\/2025.05.04.25326549"},{"key":"2026070722330594000_ciag008-B3","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang'wa","year":"2022","journal-title":"N Engl J Med"},{"key":"2026070722330594000_ciag008-B4","author":"Stop TB Partnership","year":"2025"},{"key":"2026070722330594000_ciag008-B5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/QCO.0000000000001156","article-title":"New drugs for the management of tuberculosis","volume":"38","author":"Cross","year":"2025","journal-title":"Curr Opin Infect Dis"},{"key":"2026070722330594000_ciag008-B6","author":"Working Group for New TB Drugs","year":"2025"},{"key":"2026070722330594000_ciag008-B7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1586\/14787210.2014.870884","article-title":"The early bactericidal activity of antituberculosis drugs","volume":"12","author":"Diacon","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026070722330594000_ciag008-B8","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1128\/AAC.05293-11","article-title":"Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis","volume":"55","author":"Tasneen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2026070722330594000_ciag008-B9","author":"Treatment Action Group"},{"key":"2026070722330594000_ciag008-B10","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1186\/s12879-022-07861-x","article-title":"Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis","volume":"22","author":"Pai","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2026070722330594000_ciag008-B11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1473-3099(21)00470-9","article-title":"Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study","volume":"22","author":"Ismail","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2026070722330594000_ciag008-B12","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1016\/S2666-5247(23)00172-6","article-title":"Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study","volume":"4","author":"Derendinger","year":"2023","journal-title":"Lancet Microbe"},{"key":"2026070722330594000_ciag008-B13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202506-1489OC","article-title":"Transmission of bedaquiline-resistant Mycobacterium tuberculosis in KwaZulu-Natal, South Africa","author":"Sobol","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026070722330594000_ciag008-B14","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/cid\/ciaf068","article-title":"Bedaquiline resistance and treatment outcomes among patients with tuberculosis previously exposed to bedaquiline in India: a multicentric retrospective cohort study","volume":"81","author":"Singla","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026070722330594000_ciag008-B15","doi-asserted-by":"crossref","first-page":"e00900-17","DOI":"10.1128\/AAC.00900-17","article-title":"In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China","volume":"61","author":"Pang","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026070722330594000_ciag008-B16","doi-asserted-by":"crossref","first-page":"e3391","DOI":"10.1093\/cid\/ciaa1002","article-title":"Reduced susceptibility of Mycobacterium tuberculosis to bedaquiline during antituberculosis treatment and its correlation with clinical outcomes in China","volume":"73","author":"Liu","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026070722330594000_ciag008-B17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13756-021-00995-8","article-title":"Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition","volume":"10","author":"Yao","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"key":"2026070722330594000_ciag008-B18","doi-asserted-by":"crossref","first-page":"6951","DOI":"10.2147\/IDR.S429003","article-title":"Bedaquiline resistance and molecular characterization of rifampicin-resistant Mycobacterium tuberculosis isolates in Zhejiang, China","volume":"16","author":"Tong","year":"2023","journal-title":"Infect Drug Resist"},{"key":"2026070722330594000_ciag008-B19","doi-asserted-by":"crossref","first-page":"2037961","DOI":"10.1155\/2024\/2037961","article-title":"Mycobacterium Tuberculosis lineage distribution using whole-genome sequencing and bedaquiline, clofazimine, and linezolid phenotypic profiles among rifampicin-resistant isolates from West Java, Indonesia","volume":"2024","author":"Rukmana","year":"2024","journal-title":"Int J Microbiol"},{"key":"2026070722330594000_ciag008-B20","doi-asserted-by":"crossref","first-page":"1601719","DOI":"10.1183\/13993003.01719-2016","article-title":"Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors","volume":"49","author":"Veziris","year":"2017","journal-title":"Eur Respir J"},{"key":"2026070722330594000_ciag008-B21","doi-asserted-by":"crossref","first-page":"658","DOI":"10.5588\/ijtld.21.0631","article-title":"Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan","volume":"26","author":"Nair","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026070722330594000_ciag008-B22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.5588\/ijtldopen.24.0351","article-title":"Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan","volume":"1","author":"Moe","year":"2024","journal-title":"IJTLD Open"},{"key":"2026070722330594000_ciag008-B23","doi-asserted-by":"crossref","first-page":"2100621","DOI":"10.1183\/13993003.00621-2021","article-title":"Emergence of bedaquiline resistance in a high tuberculosis burden country","volume":"59","author":"Chesov","year":"2022","journal-title":"Eur Respir J"},{"key":"2026070722330594000_ciag008-B24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cmi.2025.09.003","article-title":"High rates of acquired resistance to fluoroquinolones, bedaquiline, and linezolid in patients failing treatment against drug-resistant tuberculosis in the Republic of Moldova","volume":"32","author":"Chesov","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026070722330594000_ciag008-B25","doi-asserted-by":"crossref","first-page":"101380","DOI":"10.1016\/j.lanepe.2025.101380","article-title":"Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort study","volume":"56","author":"Kherabi","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"2026070722330594000_ciag008-B26","doi-asserted-by":"crossref","first-page":"e0002283","DOI":"10.1371\/journal.pgph.0002283","article-title":"Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid","volume":"3","author":"Timm","year":"2023","journal-title":"PLoS Global Public Health"},{"key":"2026070722330594000_ciag008-B27","doi-asserted-by":"crossref","first-page":"dlac029","DOI":"10.1093\/jacamr\/dlac029","article-title":"Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review","volume":"4","author":"Mallick","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2026070722330594000_ciag008-B28","doi-asserted-by":"crossref","first-page":"2300639","DOI":"10.1183\/13993003.00639-2023","article-title":"Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"62","author":"Perumal","year":"2023","journal-title":"Eur Respir J"},{"key":"2026070722330594000_ciag008-B29","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1186\/s12879-025-11067-2","article-title":"Prevalence of bedaquiline resistance in patients with drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"25","author":"Hu","year":"2025","journal-title":"BMC Infect Dis"},{"key":"2026070722330594000_ciag008-B30","doi-asserted-by":"crossref","first-page":"e0139017","DOI":"10.1371\/journal.pone.0139017","article-title":"Risk factors for acquired rifamycin and isoniazid resistance: a systematic review and meta-analysis","volume":"10","author":"Rockwood","year":"2015","journal-title":"PLoS One"},{"key":"2026070722330594000_ciag008-B31","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1473-3099(25)00218-X","article-title":"Treatment outcomes of bedaquiline-resistant tuberculosis: a retrospective and matched cohort study","volume":"25","author":"Mdlenyani","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026070722330594000_ciag008-B32","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1128\/AAC.01418-13","article-title":"Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug","volume":"58","author":"McLeay","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026070722330594000_ciag008-B33","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1093\/infdis\/jiaf303","article-title":"The kinetics of bedaquiline diffusion in tuberculous cavities open a window for the emergence of resistance","volume":"232","author":"Bustion","year":"2025","journal-title":"J Infect Dis"},{"key":"2026070722330594000_ciag008-B34","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur Respir J"},{"key":"2026070722330594000_ciag008-B35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"key":"2026070722330594000_ciag008-B36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-024-01289-5","article-title":"Detection of a historic reservoir of bedaquiline\/clofazimine resistance-associated variants in Mycobacterium tuberculosis","volume":"16","author":"Nimmo","year":"2024","journal-title":"Genome Med"},{"key":"2026070722330594000_ciag008-B37","doi-asserted-by":"crossref","first-page":"e151430","DOI":"10.3201\/eid2203.151430","article-title":"Global progress and challenges in implementing new medications for treating multidrug-resistant tuberculosis","volume":"22","author":"Furin","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2026070722330594000_ciag008-B38","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1183\/13993003.01891-2015","article-title":"Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence","volume":"47","author":"Pontali","year":"2016","journal-title":"Eur Respir J"},{"key":"2026070722330594000_ciag008-B39","doi-asserted-by":"crossref","first-page":"2400391","DOI":"10.1183\/13993003.00391-2024","article-title":"A composite reference standard is needed for bedaquiline antimicrobial susceptibility testing for Mycobacterium tuberculosis complex","volume":"64","author":"K\u00f6ser","year":"2024","journal-title":"Eur Respir J"},{"key":"2026070722330594000_ciag008-B40","doi-asserted-by":"crossref","first-page":"e00356-25","DOI":"10.1128\/aac.00356-25","article-title":"Unpacking bedaquiline heteroresistance: the importance of intermediate profiles for phenotypic drug susceptibility testing","volume":"69","author":"Ismail","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2026070722330594000_ciag008-B41","author":"World Health Organisation","year":"2023"},{"key":"2026070722330594000_ciag008-B42","doi-asserted-by":"crossref","first-page":"e604","DOI":"10.1016\/S2666-5247(21)00175-0","article-title":"Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis","volume":"2","author":"Ismail","year":"2021","journal-title":"Lancet Microbe"},{"key":"2026070722330594000_ciag008-B43","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2666-5247(23)00002-2","article-title":"Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis","volume":"4","author":"Sonnenkalb","year":"2023","journal-title":"Lancet Microbe"},{"key":"2026070722330594000_ciag008-B44","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1093\/cid\/cix992","article-title":"Bedaquiline resistance: its emergence, mechanism, and prevention","volume":"66","author":"Nguyen","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026070722330594000_ciag008-B45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.5588\/ijtldopen.25.0240","article-title":"Clinical best practices for caring for people with expanded resistance to newer TB drugs","volume":"2","author":"Nkomo","year":"2025","journal-title":"IJTLD Open"},{"key":"2026070722330594000_ciag008-B46","doi-asserted-by":"crossref","first-page":"230084","DOI":"10.1183\/20734735.0084-2023","article-title":"Rolling out new anti-tuberculosis drugs without diagnostic capacity","volume":"19","author":"Ness","year":"2023","journal-title":"Breathe (Sheff)"},{"key":"2026070722330594000_ciag008-B47","doi-asserted-by":"crossref","first-page":"1197.e1","DOI":"10.1016\/j.cmi.2024.03.009","article-title":"Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe","volume":"30","author":"G\u00fcnther","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026070722330594000_ciag008-B48","doi-asserted-by":"crossref","first-page":"e0081524","DOI":"10.1128\/jcm.00815-24","article-title":"Nanopore-based targeted sequencing test for direct tuberculosis identification, genotyping, and detection of drug resistance mutations: a side-by-side comparison of targeted next-generation sequencing technologies","volume":"62","author":"Cabibbe","year":"2024","journal-title":"J Clin Microbiol"},{"key":"2026070722330594000_ciag008-B49","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0140-6736(22)01883-9","article-title":"9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2\/3 non-inferiority trial in South Korea","volume":"400","author":"Mok","year":"2022","journal-title":"Lancet"},{"key":"2026070722330594000_ciag008-B50","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/S2213-2600(23)00302-8","article-title":"Global efforts to improve tuberculosis drug availability","volume":"11","author":"Burki","year":"2023","journal-title":"Lancet Respir Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag008\/66289482\/ciag008.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/6\/e1326\/66289482\/ciag008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/6\/e1326\/66289482\/ciag008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:33:53Z","timestamp":1783478033000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/6\/e1326\/8416141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,1,7]]},"published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag008","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,15]]},"published":{"date-parts":[[2026,1,7]]}}}